乳腺癌是女性激素依赖肿瘤 ,癌组织中雌激素受体 (EstrogenReceptor,ER)和孕激素受体 (ProgestoroneReceptor,PR)水平对选择内分泌治疗和预后有重要意义。但近年研究发现三苯氧胺 (TAM)治疗过程中ER表达的选择性压力、ER基因的突变及变异等 ,都是导致患者对TAM治疗的抵抗的原因 ,细胞周期素 (cyclin)D1也发现与乳腺癌的预后有一定的关系 ,本文就这些方面作一综述。 Breast cancer is a female hormone-dependent tumor. The levels of estrogen receptor (ER) and progesterone receptor (PR) in cancer tissues are important for the selection of endocrine therapy and prognosis. However, recent studies have found that the selective pressure of ER expression during the treatment of tamoxifen (TAM), the mutation and mutation of ER gene and so on are the reasons that lead to patients’ resistance to TAM therapy, and cyclin D1 is also found in breast cancer. The prognosis has a certain relationship. This article reviews these aspects.